NeuroAI NEUROAINEUROAI.SITE
China AI, reported clearly
1,300+ verified stories on models, robotics, BCI and the business of AI.
Browse stories
ESC

Ahead of Shanghai's BCI Conference, China's Brain-Computer Interface Field Confronts Its Data Bottleneck

At a media briefing for the Pujiang Innovation Forum 2026 Brain-Computer Interface Conference, neuroscientist Hong Bo framed 2026 as China's "clinical application first year" for BCI, with roughly 120 patients carrying implants for more than a month. The harder problem, he said, is building a data ecosystem that can train the next generation of decoding algorithms.

2026-11-18 · 1043 words · NeuroAI
Ahead of Shanghai's BCI Conference, China's Brain-Computer Interface Field Confronts Its Data Bottleneck

A neuroscientist stood before reporters in Shanghai this month and put a number on a field that has long traded in demos: roughly 120 patients in China are now living with a brain-computer interface implant that has stayed in place for more than a month. Then he named the problem that could slow everything down — data.

Hong Bo, chief scientist at Lingang Laboratory (临港实验室), was speaking at a media briefing for the Pujiang Innovation Forum 2026 Brain-Computer Interface Conference (浦江创新论坛2026脑机接口大会), scheduled for December 3–6 in Shanghai. He described 2026 as the field's "clinical application first year" (临床应用元年) — and, in the same breath, its "data ecosystem first year" (数据生态元年). Both labels matter. The first celebrates devices reaching patients. The second admits that the industry's next stage depends on something nobody has built yet.

From first approval to first prescription

The regulatory milestone that anchors this year came in March. On March 13, 2026, China's National Medical Products Administration approved the NEO system, an implanted brain-computer interface hand-motor compensation device developed by Shanghai-based BoRuiKang (博睿康), as what NMPA announced as the world's first approved invasive brain-computer interface medical device. The approval targets patients with tetraplegia caused by cervical spinal cord injury.

The clinical evidence behind it is now more concrete. In a follow-up of 32 tetraplegic patients implanted with NEO, 81.3% of participants showed functional recovery twelve months after surgery, with hand-grasp performance reaching clinically significant levels, according to figures presented at the briefing.

Commercially, the sequence moved quickly:

  • July 13: the first prescription for NEO was written at Huashan Hospital of Fudan University, with what organizers described as the world's first commercial implantation surgery completed the same day.
  • Twelve commercial implants have been completed to date.
  • Shanghai's Huibao (沪惠保) supplementary insurance now covers the product, reimbursing up to 30% of costs.

Coverage by a local supplemental insurance scheme is a quiet but consequential signal: BCI is starting to look like a payable medical service, not just a research program.

A crowded pipeline, not a single product

The briefing made clear that NEO is one track among several:

  • Beinao-1 (北脑一号), a Beijing Zhizhida (芯智达) product using an epidural, minimally invasive approach, has completed more than 40 human implants. Its registration trial has finished enrolling patients, with a Class III medical device filing planned for 2027.
  • NeuroXess (脑虎科技) is running what it calls a "three-complete" (三全) system — fully implanted, fully wireless, fully functional — on the subdural cortical surface route. Its GCP registration trial started at Huashan Hospital in July, which the briefing described as the first subdural implantable product in China to enter Class III registration-stage clinical trials.
  • Jieti Medical (阶梯医疗), on the fully invasive route, has completed 42 long-term implantations, which the briefing described as the most among fully invasive BCI companies globally.
  • Zhiran Medical (智冉医疗) launched a multi-center GCP trial in May for its 100-channel invasive system — the LEAP study — involving 11 medical institutions.

On the hospital side, Hong Bo said more than 20 hospitals across China have opened BCI-related clinics or wards, including Tiantan Hospital in Beijing, Huashan Hospital in Shanghai, Tianjin Huanhu Hospital and Union Hospital in Hubei.

The industrial base is concentrating in Shanghai. Qu Wei, deputy director of the Shanghai Municipal Science and Technology Commission, told the briefing that the city now hosts more than 120 BCI companies — roughly one third of the national total — with cumulative financing this year exceeding 4 billion yuan (about US$556 million), and three companies pursuing IPOs.

The data problem behind the device problem

If 2026 was about approvals and implants, the briefing's most forward-looking section was about data. Hong Bo argued that real-world EEG and neural data will be the engine of BCI industry growth — and listed the bottlenecks bluntly:

  • Data silos. Implant and trial data sit inside individual hospitals and companies, with little cross-institution flow.
  • Missing standards. There is no shared specification for data formats, quality and labeling across the field.
  • Insufficient algorithm generalization. Decoding models trained on one patient's or one center's data often fail to transfer.
  • No closed loop. Applications have not yet formed a feedback cycle in which clinical use continuously improves models.

To address this, the conference will mark the launch of a National EEG Data Center (国家脑电数据中心), led by Lingang Laboratory together with Tsinghua University and Huashan Hospital. The planned architecture is "one center plus two core nodes in Shanghai and Beijing plus a national network," linking hospitals in the Yangtze River Delta including Jiangsu and Anhui. Organizers also plan to release version 1.1 of "Youren" (游刃), a BCI data platform combining a petabyte-scale data base, multi-source data governance tools and clinical application systems.

The idea is that a national data infrastructure — pooling compliant, high-quality neural data — can do for BCI algorithms what shared datasets did for computer vision: turn scattered single-center experiments into generalizable, deployable models.

Honest limitations

Several cautions apply to this picture:

  • The "about 120 patients" figure comes from Hong Bo's statement at the briefing and is explicitly described as a rough count of patients implanted for over a month whose devices remain in place. No national registry number has been published.
  • The 81.3% twelve-month functional recovery figure is from the company's clinical follow-up as presented at the briefing, not from a peer-reviewed publication reviewed for this article.
  • The claim that Jieti Medical's 42 long-term implants are the most globally among fully invasive BCI companies rests on the briefing's own characterization; comparable public figures from other companies, including Neuralink, are not independently audited.
  • Data-ecology bottlenecks reflect expert assessment at the briefing rather than a quantified audit of the industry's data assets.

What readers can do now

  • If you cover or invest in the BCI field, track the December 3–6 conference, where the national data center launch and the "Youren 1.1" platform release will signal how data governance is actually structured.
  • Clinicians and researchers in the Yangtze River Delta region can follow the call for participation in the national data center network, since early data-sharing partners will shape standards.
  • Patients and families considering BCI trials should verify whether a specific product is in a registration-stage GCP trial and whether costs are covered by schemes such as Huibao (沪惠保), rather than relying on headline "first" claims.

Related coverage

Cite this article

NeuroAI (脑机网), "Ahead of Shanghai's BCI Conference, China's Brain-Computer Interface Field Confronts Its Data Bottleneck," 18 November 2026, https://neuroai.site/a/na-brain-hongbo-clinical-year-120-implants

Machine-readable: BibTeX · RIS · JSON · Markdown

More in “Brain–Computer Interface” → · Back to home · Markdown version

China AI, reported clearly
1,300+ verified stories on models, robotics, BCI and the business of AI.
Browse stories